WO2023227997A1 - Pharmaceutical composition containing combination of azilsartan and chlorthalidone and process of preparation thereof - Google Patents
Pharmaceutical composition containing combination of azilsartan and chlorthalidone and process of preparation thereof Download PDFInfo
- Publication number
- WO2023227997A1 WO2023227997A1 PCT/IB2023/054928 IB2023054928W WO2023227997A1 WO 2023227997 A1 WO2023227997 A1 WO 2023227997A1 IB 2023054928 W IB2023054928 W IB 2023054928W WO 2023227997 A1 WO2023227997 A1 WO 2023227997A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- azilsartan
- chlorthalidone
- control agent
- Prior art date
Links
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 title claims abstract description 62
- 229960001523 chlortalidone Drugs 0.000 title claims abstract description 59
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 49
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 239000005485 Azilsartan Substances 0.000 title claims abstract description 23
- 229960002731 azilsartan Drugs 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title abstract description 21
- 238000002360 preparation method Methods 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 34
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 239000007787 solid Substances 0.000 claims abstract description 15
- 239000008203 oral pharmaceutical composition Substances 0.000 claims abstract description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 35
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 239000007884 disintegrant Substances 0.000 claims description 9
- 238000005550 wet granulation Methods 0.000 claims description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 4
- 239000001095 magnesium carbonate Substances 0.000 claims description 4
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 4
- 239000000395 magnesium oxide Substances 0.000 claims description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 4
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 claims description 3
- 229960001545 hydrotalcite Drugs 0.000 claims description 3
- 229910001701 hydrotalcite Inorganic materials 0.000 claims description 3
- 150000007529 inorganic bases Chemical class 0.000 claims description 3
- 229960003194 meglumine Drugs 0.000 claims description 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 3
- 150000007530 organic bases Chemical class 0.000 claims description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 239000003861 C09CA09 - Azilsartan medoxomil Substances 0.000 description 49
- QJFSABGVXDWMIW-UHFFFAOYSA-N azilsartan medoxomil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C=3NC(=O)ON=3)C(OCC)=NC2=CC=CC=1C(=O)OCC=1OC(=O)OC=1C QJFSABGVXDWMIW-UHFFFAOYSA-N 0.000 description 49
- 229960004435 azilsartan kamedoxomil Drugs 0.000 description 34
- 239000000463 material Substances 0.000 description 28
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 239000003826 tablet Substances 0.000 description 21
- 239000008187 granular material Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 229960001211 azilsartan medoxomil Drugs 0.000 description 15
- 239000011248 coating agent Substances 0.000 description 12
- 238000000576 coating method Methods 0.000 description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 11
- 238000005469 granulation Methods 0.000 description 11
- 230000003179 granulation Effects 0.000 description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 11
- 239000008108 microcrystalline cellulose Substances 0.000 description 11
- 229940016286 microcrystalline cellulose Drugs 0.000 description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 10
- 229930195725 Mannitol Natural products 0.000 description 10
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 10
- 239000000594 mannitol Substances 0.000 description 10
- 235000010355 mannitol Nutrition 0.000 description 10
- 229960001855 mannitol Drugs 0.000 description 10
- 229960000913 crospovidone Drugs 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 8
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 8
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical group OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 6
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 3
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- IHWFKDWIUSZLCJ-UHFFFAOYSA-M azilsartan kamedoxomil Chemical compound [K+].C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C=3[N-]C(=O)ON=3)C(OCC)=NC2=CC=CC=1C(=O)OCC=1OC(=O)OC=1C IHWFKDWIUSZLCJ-UHFFFAOYSA-M 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 239000007891 compressed tablet Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229940103460 edarbyclor Drugs 0.000 description 3
- 239000007888 film coating Substances 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 229940049654 glyceryl behenate Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- WUAIEYMUYGBWLV-UHFFFAOYSA-M potassium;2-chloro-5-(1-hydroxy-3-oxo-2h-isoindol-1-yl)benzenesulfonamide;(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-(5-oxo-1-oxa-2-aza-4-azanidacyclopent-2-en-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate Chemical compound [K+].C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1.C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C=3[N-]C(=O)ON=3)C(OCC)=NC2=CC=CC=1C(=O)OCC=1OC(=O)OC=1C WUAIEYMUYGBWLV-UHFFFAOYSA-M 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 229940098780 tribehenin Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- -1 (5-Methyl-2-oxo- 1,3-dioxol- 4-yl)methyl Chemical group 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical class CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008019 pharmaceutical lubricant Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 239000005458 thiazide-like diuretic Substances 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Definitions
- the present subject matter relates to a solid oral pharmaceutical composition comprising combination of azilsartan medoxomil or a pharmaceutically acceptable salt thereof and chlorthalidone with at least one pharmaceutically acceptable excipient.
- the present subject matter also relates to a fixed dose pharmaceutical composition comprising azilsartan kamedoxomil and chlorthalidone with at least one pharmaceutically acceptable excipient. Furthermore, it also relates to methods for manufacturing such compositions and use thereof.
- Azilsartan is a selective ATI subtype angiotensin II receptor antagonist.
- Azilsartan medoxomil is a prodrug, which is hydrolysed to azilsartan in the gastrointestinal tract during absorption.
- the potassium salt of azilsartan medoxomil is azilsartan kamedoxomil. It is a white to nearly white powder with a molecular weight of 606.62. It is practically insoluble in water and freely soluble in methanol.
- Azilsartan kamedoxomil is chemically described as (5-Methyl-2-oxo- 1,3-dioxol- 4-yl)methyl 2-ethoxy-l- ⁇ [2'-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl) biphenyl-4- yl] methyl ⁇ - lH-benzimidazole-7-carboxylate monopotassium salt and is reported to have the following chemical structure:
- Chlorthalidone is a thiazide-like diuretic. It produces diuresis with increased excretion of sodium and chloride. It is chemically described as 2-chloro-5(l- hydroxy-3-oxo-l-isoindolinyl) benzenesulfonamide and is reported to have the following chemical structure:
- Azilsartan Kamedoxomil and its combination with chlorthalidone are approved by USFDA and are commercially available under the trade names of ED ARB I® and EDARBYCLOR® by Arbor Pharmaceuticals for the treatment of hypertension, to lower blood pressure.
- U.S. Patent No. 5,583,141 discloses compound azilsartan.
- U.S. Patent No. 7,157,584 discloses azilsartan kamedoxomil.
- U.S. Patent No. 7,572,920 discloses process of preparation of the azilsartan kamedoxomil and method for treating hypertension in combination with a diuretic.
- U.S. Patent No. 9,066,936 discloses a solid pharmaceutical composition comprising azilsartan kamedoxomil and a pH control agent, wherein the pH control agent provides a pH of 3 to 5 when dissolved or suspended in water at a concentration of 1% w/v at 25°C.
- U.S. Patent No. 9,169,238 discloses a solid pharmaceutical composition comprising azilsartan kamedoxomil, chlorthalidone and a pH control agent, wherein the pH control agent provides a pH of 2 to 5 when dissolved or suspended in water at a concentration of 1% w/v at 25°C.
- the pH control agent is preferably monosodium fumarate or a combination of fumaric acid and sodium ion donor. In addition, fumaric acid and sodium hydroxide may be used in combination.
- Indian Patent application 5882/CHE/2013 discloses tablet composition comprising azilsartan kamedoxomil and pH regulating agent having a pH not less than 5. It also discloses that composition optionally comprises second active agent.
- Indian Patent application IN202041035039 discloses stable pharmaceutical compositions comprising azilsartan kamedoxomil and/or combination with chlorthalidone and a pH regulating agent magnesium aluminometasilicate having a pH in the range of 7 to 12 when dissolved or suspended in water at a concentration of 1% w/v at 25°C.
- the present subject matter relates to a pharmaceutical composition
- a pharmaceutical composition comprising azilsartan kamedoxomil and/or combination with chlorthalidone and pH control agent with one or more suitable pharmaceutically acceptable excipients.
- the pH control agent/s as per this disclosure typically exhibits a pH of more than 5.0, preferably about 5.0 to about 7.0, about 5.0 to about 6.0 and more preferably about 5.5 to 6.0.
- a pH control agent such as: a strong acid such as hydrochloric acid, sulfuric acid, phosphoric acid and like; basic substance such as inorganic bases (e.g., sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogen carbonate, magnesium carbonate, calcium carbonate, magnesium oxide, ammonia, synthetic hydrotalcite), organic bases (e.g., basic amino acid such as lysine, arginine, etc., meglumine, and the like); methacrylic acid copolymer such as methacrylic acid and ethyl acrylate cop
- the present subject matter relates to a stable pharmaceutical composition comprising azilsartan kamedoxomil and/or combination with chlorthalidone and such pH control agent as described above, with one more pharmaceutically acceptable excipient(s).
- the present subject matter also provides a stable, economically and industrially feasible process for preparing pharmaceutical compositions comprising azilsartan kamedoxomil and/or combination with chlorthalidone and desired pH control agent with one or more suitable pharmaceutically acceptable excipients.
- the present subject matter relates to a solid oral pharmaceutical composition comprising combination of azilsartan and chlorthalidone or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. Furthermore, it also relates to methods for manufacturing such compositions, and uses thereof.
- An aspect of the present subject matter is to provide a solid oral pharmaceutical composition comprising combination of azilsartan kamedoxomil and chlorthalidone or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. Furthermore, it also relates to methods for manufacturing such compositions, and uses thereof.
- An aspect of the present subject matter is to provide a pharmaceutical composition with improved stability and dissolution of azilsartan kamedoxomil and chlorthalidone or pharmaceutically acceptable salt thereof and a process of manufacturing the pharmaceutical composition thereof.
- An aspect of the present subject matter is to provide a stable pharmaceutical compositions comprising combination of azilsartan kamedoxomil with chlorthalidone and a pH control agent that provides a pH of more than 5.0, preferably about 5.0 to about 7.0, about 5.0 to about 6.0 and more preferably about 5.5 to 6.0 with one more pharmaceutically acceptable excipient(s).
- Another aspect of the present subject matter is to provide a pharmaceutical composition with improved stability and dissolution of azilsartan kamedoxomil using a pH control agent that provides a pH of more than 5.0, preferably about 5.0 to about 7.0, about 5.0 to about 6.0 and more preferably about 5.5 to 6.0 with one more pharmaceutically acceptable excipient(s).
- Another aspect of the present subject matter is to provide a pharmaceutical composition with improved stability and dissolution of azilsartan kamedoxomil using a strong acid as a pH control agent that provides a pH of more than 5.0, preferably about 5.0 to about 7.0, about 5.0 to about 6.0 and more preferably about 5.5 to 6.0 with one more pharmaceutically acceptable excipient(s).
- the acid is hydrochloric acid .
- Another aspect of the present subject matter is to provide a pharmaceutical composition with improved stability and dissolution of azilsartan kamedoxomil and chlorthalidone or a pharmaceutically acceptable salt thereof using hydrochloric acid as a pH control agent, adjusted to provide a pH of more than 5.0, preferably about 5.0 to about 7.0, about 5.0 to about 6.0 and more preferably about 5.5 to 6.0 with one more pharmaceutically acceptable excipient(s).
- a process to prepare the pharmaceutical compositions of the present subject matter involves wet granulation.
- the wet granulation process involves rapid mixer granulator. In another embodiment, the wet granulation process involves fluidized bed processor.
- the pharmaceutical composition of the present subject matter is prepared by separately granulating azilsartan kamedoxomil and chlorthalidone or a pharmaceutically acceptable salt thereof, and then blending both the granules, optionally with extragranular material to obtain final dosage form.
- azilsartan kamedoxomil can be stabilized to prepare stable pharmaceutical compositions comprising azilsartan kamedoxomil and/or combination with chlorthalidone by utilizing a single pH control agent.
- composition is intended to encompass a product comprising the specified ingredients, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.
- the pH control agent as per the present subject matter may be any pharmaceutically acceptable ingredient that provides the desired pH and simultaneously achieves desired stability and dissolution of active ingredient/s.
- the pH of the pH control agent refers to an observed pH obtained by dissolving or suspending a pH control agent in water at a concentration of 1% w/v at 25. degree. C.
- intra-granular or intra-granular portion includes, but is not limited to, a part or component of composition mixed or blended to form granules.
- extra-granular or extra-granular portion includes, but is not limited to, a part or component of composition mixed or blended with dry mix formed after granulation, lubricated, and which is further subjected to compression to form the tablets and coating the tablets.
- a composition of the present subject matter is prepared by separately granulating azilsartan part and chlorthalidone part and compressing both the granules to form the tablets.
- the composition containing azilsartan and chlorthalidone or pharmaceutically acceptable salt thereof is prepared by a process comprising following steps, a) granulating a blend of azilsartan kamedoxomil and one or more pharmaceutically acceptable excipients by wet granulation process, using a granulation medium containing a pH control agent dissolved in a suitable solvent, b) separately granulating intragranular excipients using a granulation medium containing chlorthalidone dissolved in a suitable solvent to prepare chlorthalidone granules, d) blending azilsartan and chlorthalidone part granules with extragranular excipients to obtain final blend, e) compressing the final blend to form a tablet and coating the tablet.
- a composition of the present subject matter is prepared by separately granulating azilsartan part, chlorthalidone part and placebo granules part and compressing all the granules to form tablets.
- a composition containing azilsartan and chlorthalidone or a pharmaceutically acceptable salt thereof is prepared by a process comprising following steps, a) granulating a blend of azilsartan kamedoxomil and one or more pharmaceutically acceptable excipients by wet granulation process using a suitable solvent to prepare azilsartan granules, b) preparing separate placebo granules by granulating intragranular excipients with a granulating medium containing a pH control agent, and c) separately granulating intragranular excipients using a granulation medium containing chlorthalidone dissolved in a suitable solvent to prepare chlorthalidone granules, d) blending azilsartan, chlorthalidone and placebo part granules with extragranular excipients to obtain final blend, e) compressing the final blend to form tablet and coating the tablet.
- the composition of the present subject matter is stable for at least one month under packed condition. In embodiments, the composition of the present subject matter is stable for at least two months under packed condition. In embodiments, the composition of the present subject matter is stable for at least six months under packed condition.
- composition comprising,
- composition comprising,
- composition comprising,
- composition comprising,
- composition comprising,
- composition comprising,
- composition (f) one or more pharmaceutically acceptable lubricant.
- a pharmaceutical composition is prepared by a process involving wet granulation in rapid mixer granulator.
- Another aspect of the present subject matter provides a pharmaceutical composition comprising,
- composition (g) one or more pharmaceutically acceptable lubricant. wherein a pharmaceutical composition is prepared by a process involving wet granulation in fluidized bed granulator.
- the excipients include one or more of pH control agents, diluents, binders, disintegrants and lubricants.
- pH control agent is intended to be interpreted in the context of pharmaceutical formulation science.
- Suitable pH control agent can be selected from the group of, but not limited to strong acids such as hydrochloric acid, sulfuric acid, phosphoric acid and like; basic substances include inorganic bases (e.g., sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogen carbonate, magnesium carbonate, calcium carbonate, magnesium oxide, ammonia, synthetic hydrotalcite), organic bases (e.g., basic amino acid such as lysine, arginine, etc., meglumine, and the like); methacrylic acid copolymer such as methacrylic acid and ethyl acrylate copolymer e.g. Eudragit LI 00-55 and the like.
- diluent is intended to be interpreted in the context of pharmaceutical formulation science. Suitable diluents can be selected from the group of, but not limited to microcrystalline cellulose (MCC), pregelatinized starch, sugar and sugar alcohol such as mannitol, lactose, fructose, isomalt, lactitol, maltitol, sorbitol, erythritol, maltose, polydextrose, sucrose, trehalose, xylitol, calcium carbonate, dicalcium phosphate, calcium sulfate, cellulose acetate, ethylcellulose, inulin, magnesium carbonate, magnesium oxide, maltodextrin, sodium bicarbonate, sodium carbonate and sodium chloride.
- MCC microcrystalline cellulose
- sugar alcohol such as mannitol, lactose, fructose, isomalt, lactitol, maltitol, sorbitol, erythritol
- binder is intended to be interpreted in the context of pharmaceutical formulation science.
- Suitable binder can be selected from the group of, but not limited to povidone, copovidone pregelatinized starch, cellulose, methyl cellulose, ethyl cellulose, cellulose derivatives (e.g., hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC)), polyethylene glycol and hydroxypropyl methyl cellulose acetate succinate (HPMC-AS).
- disintegrant and “disintegrants” are intended to be interpreted in the context of pharmaceutical formulation science.
- Suitable disintegrants according to the present subject matter can be selected from but not limited to crospovidone, croscarmellose sodium (CCS), sodium starch glycolate (SSG), pregelatinized starch, alginic acid, sodium alginate, carboxymethylcellulose calcium, chitosan, crospovidone, glycine, guar gum, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, magnesium aluminum silicate, methylcellulose, povidone, sodium alginate, sodium carboxymethylcellulose and starch.
- CCS croscarmellose sodium
- SSG sodium starch glycolate
- pregelatinized starch alginic acid, sodium alginate, carboxymethylcellulose calcium, chitosan, crospovidone, glycine, guar gum, hydroxypropyl cellulose, low-substituted hydroxypropyl
- lubricant and “lubricants” are intended to be interpreted in the context of pharmaceutical formulation science.
- Suitable pharmaceutical lubricant according to the present subject matter can be selected from but not limited to magnesium, aluminium, zinc or calcium stearate, glyceryl behenate, glyceryl dibehenate, glyceryl monostearate, glyceryl palmitostearate, a mixture of behenate esters of glycerine (e.g.
- the organic solvent suitable for preparing a composition is selected from isopropyl alcohol, ethanol, methanol, acetone, dichloromethane, acetonitrile, petroleum ether or mixture thereof.
- a pharmaceutical tablet comprising the pharmaceutical composition as defined herein.
- a pharmaceutical tablet comprising a pharmaceutical composition in the form of tablet core, wherein the tablet core is coated with a layer of coating.
- the coating is a film coating.
- the film coating may be applied using conventional methods.
- a coating can be used to provide protection against, for example, moisture ingress or degradation by light, to colour the formulation, or to modify or control the release of azilsartan and chlorthalidone from the formulation.
- a pharmaceutical composition is a pharmaceutical tablet.
- the pharmaceutical composition is a pharmaceutical tablet composition suitable for oral administration to a human.
- the pharmaceutical tablet comprises 40 mg of Azilsartan base which is equivalent to 42.68 mg of azilsartan kamedoxomil.
- the pharmaceutical tablet comprises 12.5 mg and 25 mg Chlorthalidone.
- a pharmaceutical composition as defined herein, for use as a medicament.
- a method of using pharmaceutical composition comprising an effective amount of azilsartan kamedoxomil, and chlorthalidone with one or more pharmaceutically acceptable excipient in the treatment of hypertension.
- Acetone was dispensed and mixed with acidified water of step 2 in the ratio of 95:5.
- a pH of 1% w/w of acidified acetone in water is 5.6-5.7.
- step 1 Sifted material of step 1 was dry mixed in rapid mixer granulator for 10-15 minutes.
- step 4 The dry mix material of step 4 was granulated with acidified acetone of step 3.
- the granulated wet mass was dried in rapid dryer at 50-60°C and dried material was milled in quadro co-mill.
- step 3 Sifted material of step 1 was loaded in fluidized bed processor (FBP).
- FBP fluidized bed processor
- step 3 Material of step 3 was wet granulated in FBP with the drug solution of step 2.
- the granulated wet mass was dried in rapid dryer at 50-60°C and dried material was milled in quadro co-mill.
- Extragranular material containing mannitol, microcrystalline cellulose, crospovidone and magnesium stearate were dispensed and sifted through quadro sifter.
- step 2 The sifted material of step 1 was blended with Azilsartan and chlorthalidone granules in a bin blender for 10-15 minutes.
- the lubricated blend was compressed using suitable punch tooling.
- the compressed tablets were film coated with aqueous dispersion of step 4 in a perforated coating pan.
- step 2 Sifted material of step 1 was dry mixed in rapid mixer granulator for 10-15 minutes.
- step 3 The dry mix material of step 2 was granulated with acetone.
- step 4 The granulated wet mass was dried in rapid dryer at 50-60°C and dried material was milled in quadro co-mill. Placebo granulation part Intragranular excipients mannitol and microcrystalline cellulose were dispensed and sifted in quadro sifter. Purified water was taken in container and added to 37% w/v hydrochloric acid. A pH of 1% w/w acidified water is 5.6-5.7. Sifted material of step 1 was dry mixed in rapid mixer granulator for 10-15 minutes. The dry mix material of step 3 was granulated with acidified water of step
- the granulated wet mass was dried in rapid dryer at 50-60°C and dried material was milled in quadro co-mill.
- Chlorthalidone granulation part Intragranular excipients mannitol, microcrystalline cellulose and crospovidone were dispensed and sifted in quadro sifter. Chlorthalidone was dissolved in methanol. Sifted material of step 1 was loaded in fluidized bed processor (FBP). Material of step 3 was wet granulated in FBP with the drug solution of step 2. The granulated wet mass was dried in rapid dryer at 50-60°C and dried material was milled in quadro co-mill.
- FBP fluidized bed processor
- Extragranular material containing crospovidone and magnesium stearate were dispensed and sifted through quadro sifter.
- the sifted material of step 1 was blended with Azilsartan granules, chlorthalidone granules and placebo granules in a bin blender for 10-15 minutes.
- the lubricated blend was compressed using suitable punch tooling. Opadry was dispersed in water under stirring. 5.
- the compressed tablets were film coated with aqueous dispersion of step 4 in a perforated coating pan.
- step 1 Hydrochloric acid (37% w/v) was taken in container and added to acetone. A pH of 1% w/w acidified acetone is 5.8-6.1. 3. Sifted material of step 1 was dry mixed in rapid mixer granulator for 10-15 minutes.
- step 4 The dry mix material of step 4 was granulated with acidified acetone of step 3.
- the granulated wet mass was dried in rapid dryer at 50-60°C and dried material was milled in quadro co-mill.
- step 3 Sifted material of step 1 was loaded in fluidized bed processor (FBP).
- FBP fluidized bed processor
- step 3 Material of step 3 was wet granulated in FBP with the drug solution of step 2.
- the granulated wet mass was dried in rapid dryer at 50-60°C and dried material was milled in quadro co-mill.
- Extragranular material containing mannitol, microcrystalline cellulose, crospovidone and magnesium stearate were dispensed and sifted through quadro sifter.
- step 2 The sifted material of step 1 was blended with Azilsartan and chlorthalidone granules in a bin blender for 10-15 minutes.
- the lubricated blend was compressed using suitable punch tooling.
- the compressed tablets were film coated with aqueous dispersion of step 4 in a perforated coating pan.
Abstract
The present subject matter relates to a solid oral pharmaceutical composition comprising combination of azilsartan and chlorthalidone or a pharmaceutically acceptable salt thereof with at least one pharmaceutically acceptable excipient. The present subject matter also relates to a fixed dose pharmaceutical composition comprising azilsartan and chlorthalidone or a pharmaceutically acceptable salt thereof with at least one pharmaceutically acceptable excipient. Furthermore, it also relates to methods for manufacturing such compositions and use thereof.
Description
PHARMACEUTICAL COMPOSITION CONTAINING COMBINATION OF AZILSARTAN AND CHLORTHALIDONE AND PROCESS OF PREPARATION THEREOF
TECHNICAL FIELD
The present subject matter relates to a solid oral pharmaceutical composition comprising combination of azilsartan medoxomil or a pharmaceutically acceptable salt thereof and chlorthalidone with at least one pharmaceutically acceptable excipient. The present subject matter also relates to a fixed dose pharmaceutical composition comprising azilsartan kamedoxomil and chlorthalidone with at least one pharmaceutically acceptable excipient. Furthermore, it also relates to methods for manufacturing such compositions and use thereof.
BACKGROUND
Azilsartan is a selective ATI subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a prodrug, which is hydrolysed to azilsartan in the gastrointestinal tract during absorption. The potassium salt of azilsartan medoxomil is azilsartan kamedoxomil. It is a white to nearly white powder with a molecular weight of 606.62. It is practically insoluble in water and freely soluble in methanol.
Azilsartan kamedoxomil, is chemically described as (5-Methyl-2-oxo- 1,3-dioxol- 4-yl)methyl 2-ethoxy-l-{ [2'-(5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl) biphenyl-4- yl] methyl}- lH-benzimidazole-7-carboxylate monopotassium salt and is reported to have the following chemical structure:
Chlorthalidone is a thiazide-like diuretic. It produces diuresis with increased excretion of sodium and chloride. It is chemically described as 2-chloro-5(l- hydroxy-3-oxo-l-isoindolinyl) benzenesulfonamide and is reported to have the following chemical structure:
Azilsartan Kamedoxomil and its combination with chlorthalidone are approved by USFDA and are commercially available under the trade names of ED ARB I® and EDARBYCLOR® by Arbor Pharmaceuticals for the treatment of hypertension, to lower blood pressure.
U.S. Patent No. 5,583,141 discloses compound azilsartan. U.S. Patent No. 7,157,584 discloses azilsartan kamedoxomil. U.S. Patent No. 7,572,920 discloses process of preparation of the azilsartan kamedoxomil and method for treating hypertension in combination with a diuretic.
U.S. Patent No. 9,066,936 discloses a solid pharmaceutical composition comprising azilsartan kamedoxomil and a pH control agent, wherein the pH control agent provides a pH of 3 to 5 when dissolved or suspended in water at a concentration of 1% w/v at 25°C.
U.S. Patent No. 9,169,238 discloses a solid pharmaceutical composition comprising azilsartan kamedoxomil, chlorthalidone and a pH control agent, wherein the pH control agent provides a pH of 2 to 5 when dissolved or suspended in water at a concentration of 1% w/v at 25°C. The pH control agent is preferably monosodium fumarate or a combination of fumaric acid and sodium ion donor. In addition, fumaric acid and sodium hydroxide may be used in combination.
Indian Patent application 5882/CHE/2013 discloses tablet composition comprising azilsartan kamedoxomil and pH regulating agent having a pH not less than 5. It also discloses that composition optionally comprises second active agent.
Indian Patent application IN202041035039 discloses stable pharmaceutical compositions comprising azilsartan kamedoxomil and/or combination with chlorthalidone and a pH regulating agent magnesium aluminometasilicate having a pH in the range of 7 to 12 when dissolved or suspended in water at a concentration of 1% w/v at 25°C.
There still remains a need to provide a stable pharmaceutical composition containing azilsartan medoxomil or a salt there of with desired dissolution and bioavailability parameters.
The present subject matter relates to a pharmaceutical composition comprising azilsartan kamedoxomil and/or combination with chlorthalidone and pH control agent with one or more suitable pharmaceutically acceptable excipients.
The pH control agent/s as per this disclosure typically exhibits a pH of more than 5.0, preferably about 5.0 to about 7.0, about 5.0 to about 6.0 and more preferably about 5.5 to 6.0.
As part of developmental efforts, it was surprisingly found out that, azilsartan kamedoxomil can be stabilized to prepare stable pharmaceutical compositions comprising azilsartan kamedoxomil and/or combination with chlorthalidone by utilizing a pH control agent such as: a strong acid such as hydrochloric acid, sulfuric acid, phosphoric acid and like; basic substance such as inorganic bases (e.g., sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogen carbonate, magnesium carbonate, calcium carbonate, magnesium oxide, ammonia, synthetic hydrotalcite), organic bases (e.g., basic amino acid such as lysine, arginine, etc., meglumine, and the like); methacrylic acid copolymer such as methacrylic acid and ethyl acrylate copolymer e.g. Eudragit LI 00-55 and the like. It was also surprisingly found out that the satisfactory stability can be achieved by employing a single pH control agent. This is in contrary to the existing prior art for example US9,066,936 and US9, 169,238, which require combination of acid, such as fumaric acid and base, such as sodium hydroxide. Accordingly, the present subject matter relates to a stable pharmaceutical composition comprising azilsartan kamedoxomil and/or combination with chlorthalidone and such pH control agent as described above, with one more pharmaceutically acceptable excipient(s).
The present subject matter also provides a stable, economically and industrially feasible process for preparing pharmaceutical compositions comprising azilsartan kamedoxomil and/or combination with chlorthalidone and desired pH control agent with one or more suitable pharmaceutically acceptable excipients.
SUMMARY OF THE SUBJECT MATTER
The present subject matter relates to a solid oral pharmaceutical composition comprising combination of azilsartan and chlorthalidone or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
Furthermore, it also relates to methods for manufacturing such compositions, and uses thereof.
An aspect of the present subject matter is to provide a solid oral pharmaceutical composition comprising combination of azilsartan kamedoxomil and chlorthalidone or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. Furthermore, it also relates to methods for manufacturing such compositions, and uses thereof.
An aspect of the present subject matter is to provide a pharmaceutical composition with improved stability and dissolution of azilsartan kamedoxomil and chlorthalidone or pharmaceutically acceptable salt thereof and a process of manufacturing the pharmaceutical composition thereof.
An aspect of the present subject matter is to provide a stable pharmaceutical compositions comprising combination of azilsartan kamedoxomil with chlorthalidone and a pH control agent that provides a pH of more than 5.0, preferably about 5.0 to about 7.0, about 5.0 to about 6.0 and more preferably about 5.5 to 6.0 with one more pharmaceutically acceptable excipient(s).
Another aspect of the present subject matter is to provide a pharmaceutical composition with improved stability and dissolution of azilsartan kamedoxomil using a pH control agent that provides a pH of more than 5.0, preferably about 5.0 to about 7.0, about 5.0 to about 6.0 and more preferably about 5.5 to 6.0 with one more pharmaceutically acceptable excipient(s).
Another aspect of the present subject matter is to provide a pharmaceutical composition with improved stability and dissolution of azilsartan kamedoxomil using a strong acid as a pH control agent that provides a pH of more than 5.0, preferably about 5.0 to about 7.0, about 5.0 to about 6.0 and more preferably
about 5.5 to 6.0 with one more pharmaceutically acceptable excipient(s). In an aspect, the acid is hydrochloric acid .
Another aspect of the present subject matter is to provide a pharmaceutical composition with improved stability and dissolution of azilsartan kamedoxomil and chlorthalidone or a pharmaceutically acceptable salt thereof using hydrochloric acid as a pH control agent, adjusted to provide a pH of more than 5.0, preferably about 5.0 to about 7.0, about 5.0 to about 6.0 and more preferably about 5.5 to 6.0 with one more pharmaceutically acceptable excipient(s).
In an embodiment of the present subject matter, a process to prepare the pharmaceutical compositions of the present subject matter involves wet granulation.
In an embodiment, the wet granulation process involves rapid mixer granulator. In another embodiment, the wet granulation process involves fluidized bed processor.
In an embodiment, the pharmaceutical composition of the present subject matter is prepared by separately granulating azilsartan kamedoxomil and chlorthalidone or a pharmaceutically acceptable salt thereof, and then blending both the granules, optionally with extragranular material to obtain final dosage form.
DETAILED DESCRIPTION OF THE SUBJECT MATTER:
An object of the present subject matter is to provide a solid pharmaceutical composition with improved stability and dissolution of azilsartan kamedoxomil and/or chlorthalidone or a pharmaceutically acceptable salt thereof.
Another object of the present subject matter is to provide a method of stabilizing azilsartan kamedoxomil and/or chlorthalidone or a pharmaceutically acceptable salt thereof and further, a method of improving dissolution thereof.
It was found out that, azilsartan kamedoxomil can be stabilized to prepare stable pharmaceutical compositions comprising azilsartan kamedoxomil and/or combination with chlorthalidone by utilizing a single pH control agent.
As used herein, "a" or "an" means one or more unless otherwise specified.
The term "composition" is intended to encompass a product comprising the specified ingredients, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.
The pH control agent as per the present subject matter may be any pharmaceutically acceptable ingredient that provides the desired pH and simultaneously achieves desired stability and dissolution of active ingredient/s.
To be precise, the pH of the pH control agent refers to an observed pH obtained by dissolving or suspending a pH control agent in water at a concentration of 1% w/v at 25. degree. C.
The term “intra-granular or intra-granular portion” as used herein includes, but is not limited to, a part or component of composition mixed or blended to form granules.
The term “extra-granular or extra-granular portion” as used herein includes, but is not limited to, a part or component of composition mixed or blended with dry mix formed after granulation, lubricated, and which is further subjected to compression to form the tablets and coating the tablets.
In an embodiment, a composition of the present subject matter is prepared by separately granulating azilsartan part and chlorthalidone part and compressing both the granules to form the tablets.
In an embodiment, the composition containing azilsartan and chlorthalidone or pharmaceutically acceptable salt thereof is prepared by a process comprising following steps, a) granulating a blend of azilsartan kamedoxomil and one or more pharmaceutically acceptable excipients by wet granulation process, using a granulation medium containing a pH control agent dissolved in a suitable solvent, b) separately granulating intragranular excipients using a granulation medium containing chlorthalidone dissolved in a suitable solvent to prepare chlorthalidone granules, d) blending azilsartan and chlorthalidone part granules with extragranular excipients to obtain final blend, e) compressing the final blend to form a tablet and coating the tablet.
In one embodiment, a composition of the present subject matter is prepared by separately granulating azilsartan part, chlorthalidone part and placebo granules part and compressing all the granules to form tablets.
In an embodiment, a composition containing azilsartan and chlorthalidone or a pharmaceutically acceptable salt thereof is prepared by a process comprising following steps, a) granulating a blend of azilsartan kamedoxomil and one or more pharmaceutically acceptable excipients by wet granulation process using a suitable solvent to prepare azilsartan granules, b) preparing separate placebo granules by granulating intragranular excipients with a granulating medium containing a pH control agent, and
c) separately granulating intragranular excipients using a granulation medium containing chlorthalidone dissolved in a suitable solvent to prepare chlorthalidone granules, d) blending azilsartan, chlorthalidone and placebo part granules with extragranular excipients to obtain final blend, e) compressing the final blend to form tablet and coating the tablet.
In one embodiment, the composition of the present subject matter is stable for at least one month under packed condition. In embodiments, the composition of the present subject matter is stable for at least two months under packed condition. In embodiments, the composition of the present subject matter is stable for at least six months under packed condition.
Another aspect of the present subject matter provides a pharmaceutical composition comprising,
(a) azilsartan medoxomil or a pharmaceutically acceptable salt thereof,
(b) chlorthalidone,
(c) one or more pharmaceutically acceptable excipient.
Another aspect of the present subject matter provides a pharmaceutical composition comprising,
(a) azilsartan medoxomil or a pharmaceutically acceptable salt thereof,
(b) chlorthalidone,
(c) pharmaceutically acceptable pH control agent,
(d) one or more pharmaceutically acceptable excipient.
Another aspect of the present subject matter provides a pharmaceutical composition comprising,
(a) azilsartan medoxomil or a pharmaceutically acceptable salt thereof,
(b) chlorthalidone,
(c) pharmaceutically acceptable pH control agent,
(d) one or more pharmaceutically acceptable diluent,
(e) one or more pharmaceutically acceptable disintegrant,
(f) one or more pharmaceutically acceptable lubricant.
Another aspect of the present subject matter provides a pharmaceutical composition comprising,
(a) azilsartan kamedoxomil,
(b) chlorthalidone,
(c) pharmaceutically acceptable pH control agent,
(d) one or more pharmaceutically acceptable diluent,
(e) one or more pharmaceutically acceptable disintegrant,
(f) one or more pharmaceutically acceptable lubricant.
Another aspect of the present subject matter provides a pharmaceutical composition comprising,
(a) azilsartan medoxomil or a pharmaceutically acceptable salt thereof,
(b) chlorthalidone or a pharmaceutically acceptable salt thereof,
(c) one or more pharmaceutically acceptable excipient, wherein a pharmaceutical composition is prepared by wet granulation.
Another aspect of the present subject matter provides a pharmaceutical composition comprising,
(a) azilsartan medoxomil or a pharmaceutically acceptable salt thereof,
(b) chlorthalidone,
(c) pharmaceutically acceptable pH control agent,
(d) one or more pharmaceutically acceptable diluent,
(e) one or more pharmaceutically acceptable disintegrant,
(f) one or more pharmaceutically acceptable lubricant. wherein a pharmaceutical composition is prepared by a process involving wet granulation in rapid mixer granulator.
Another aspect of the present subject matter provides a pharmaceutical composition comprising,
(a) azilsartan kamedoxomil,
(b) chlorthalidone,
(c) pharmaceutically acceptable pH control agent,
(d) one or more pharmaceutically acceptable diluent,
(e) one or more pharmaceutically acceptable binder,
(f) one or more pharmaceutically acceptable disintegrant.
(g) one or more pharmaceutically acceptable lubricant. wherein a pharmaceutical composition is prepared by a process involving wet granulation in fluidized bed granulator.
According to one embodiment, the excipients include one or more of pH control agents, diluents, binders, disintegrants and lubricants.
The term “pH control agent” is intended to be interpreted in the context of pharmaceutical formulation science. Suitable pH control agent can be selected from the group of, but not limited to strong acids such as hydrochloric acid, sulfuric acid, phosphoric acid and like; basic substances include inorganic bases (e.g., sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogen carbonate, magnesium carbonate, calcium carbonate, magnesium oxide, ammonia, synthetic hydrotalcite), organic bases (e.g., basic amino acid such as lysine, arginine, etc., meglumine, and the like); methacrylic acid copolymer such as methacrylic acid and ethyl acrylate copolymer e.g. Eudragit LI 00-55 and the like.
The term “diluent” is intended to be interpreted in the context of pharmaceutical formulation science. Suitable diluents can be selected from the group of, but not limited to microcrystalline cellulose (MCC), pregelatinized starch, sugar and sugar alcohol such as mannitol, lactose, fructose, isomalt, lactitol, maltitol, sorbitol, erythritol, maltose, polydextrose, sucrose, trehalose, xylitol, calcium
carbonate, dicalcium phosphate, calcium sulfate, cellulose acetate, ethylcellulose, inulin, magnesium carbonate, magnesium oxide, maltodextrin, sodium bicarbonate, sodium carbonate and sodium chloride.
The term “binder” is intended to be interpreted in the context of pharmaceutical formulation science. Suitable binder can be selected from the group of, but not limited to povidone, copovidone pregelatinized starch, cellulose, methyl cellulose, ethyl cellulose, cellulose derivatives (e.g., hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC)), polyethylene glycol and hydroxypropyl methyl cellulose acetate succinate (HPMC-AS).
The terms “disintegrant” and “disintegrants” are intended to be interpreted in the context of pharmaceutical formulation science. Suitable disintegrants according to the present subject matter can be selected from but not limited to crospovidone, croscarmellose sodium (CCS), sodium starch glycolate (SSG), pregelatinized starch, alginic acid, sodium alginate, carboxymethylcellulose calcium, chitosan, crospovidone, glycine, guar gum, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, magnesium aluminum silicate, methylcellulose, povidone, sodium alginate, sodium carboxymethylcellulose and starch.
The terms “lubricant” and “lubricants” are intended to be interpreted in the context of pharmaceutical formulation science. Suitable pharmaceutical lubricant according to the present subject matter can be selected from but not limited to magnesium, aluminium, zinc or calcium stearate, glyceryl behenate, glyceryl dibehenate, glyceryl monostearate, glyceryl palmitostearate, a mixture of behenate esters of glycerine (e.g. a mixture of glyceryl behenate, tribehenin and glyceryl behenate), magnesium stearate, myristic acid, palmitic acid, stearic acid, talc, tribehenin, sodium stearyl fumarate (SSF) and sucrose stearate.
In an embodiment of the present subject matter, the organic solvent suitable for preparing a composition is selected from isopropyl alcohol, ethanol, methanol, acetone, dichloromethane, acetonitrile, petroleum ether or mixture thereof.
As used herein, the word “comprising” describes components that must be present, but leaves open the possibility that other unspecified components may also be present within the scope of the relevant term.
In one aspect there is provided a pharmaceutical tablet comprising the pharmaceutical composition as defined herein.
In one embodiment there is provided a pharmaceutical tablet comprising a pharmaceutical composition in the form of tablet core, wherein the tablet core is coated with a layer of coating. In one embodiment the coating is a film coating.
When the tablet has a film coating, the film coating may be applied using conventional methods. A coating can be used to provide protection against, for example, moisture ingress or degradation by light, to colour the formulation, or to modify or control the release of azilsartan and chlorthalidone from the formulation.
In one embodiment, a pharmaceutical composition is a pharmaceutical tablet.
In one embodiment, the pharmaceutical composition is a pharmaceutical tablet composition suitable for oral administration to a human.
In one embodiment, the pharmaceutical tablet comprises 40 mg of Azilsartan base which is equivalent to 42.68 mg of azilsartan kamedoxomil.
In one embodiment, the pharmaceutical tablet comprises 12.5 mg and 25 mg Chlorthalidone.
In one aspect, there is provided a pharmaceutical composition, as defined herein, for use as a medicament.
In one embodiment, there is provided a method of using pharmaceutical composition comprising an effective amount of azilsartan kamedoxomil, and chlorthalidone with one or more pharmaceutically acceptable excipient in the treatment of hypertension.
It is to be understood that each of the variously stated ranges is intended to be continuous so as to include each numerical parameter between the stated minimum and maximum value of each range.
Embodiments provided herein may be more fully understood by reference to the following examples. These examples are meant to be illustrative of pharmaceutical composition and dosage form provided herein, but is not in any way limiting.
Example 1:
Table 1-Pharmaceutical composition of Azilsartan and Chlorthalidone
Example 2
Table 2 - Pharmaceutical composition of Azilsartan and Chlorthalidone
Procedure for Example 2
Azilsartan kamedoxomil granulation part
1. Azilsartan Medoxomil Monopotassium along with intragranular excipients mannitol, microcrystalline cellulose and hydroxypropyl cellulose were dispensed and sifted in quadro sifter.
2. Purified water was taken in container and added to 37% w/v hydrochloric acid. A pH of 1% w/w acidified water is 5.6-5.7.
3. Acetone was dispensed and mixed with acidified water of step 2 in the ratio of 95:5. A pH of 1% w/w of acidified acetone in water is 5.6-5.7.
4. Sifted material of step 1 was dry mixed in rapid mixer granulator for 10-15 minutes.
5. The dry mix material of step 4 was granulated with acidified acetone of step 3.
6. The granulated wet mass was dried in rapid dryer at 50-60°C and dried material was milled in quadro co-mill.
Chlorthalidone granulation part
1. Intragranular excipients mannitol, microcrystalline cellulose and crospovidone were dispensed and sifted in quadro sifter.
2. Chlorthalidone was dissolved in methanol.
3. Sifted material of step 1 was loaded in fluidized bed processor (FBP).
4. Material of step 3 was wet granulated in FBP with the drug solution of step 2.
5. The granulated wet mass was dried in rapid dryer at 50-60°C and dried material was milled in quadro co-mill.
Compression and coating
1. Extragranular material containing mannitol, microcrystalline cellulose, crospovidone and magnesium stearate were dispensed and sifted through quadro sifter.
2. The sifted material of step 1 was blended with Azilsartan and chlorthalidone granules in a bin blender for 10-15 minutes.
3. The lubricated blend was compressed using suitable punch tooling.
4. Opadry was dispersed in water under stirring.
5. The compressed tablets were film coated with aqueous dispersion of step 4 in a perforated coating pan.
Example 3
Table 3 - Pharmaceutical composition of Azilsartan and Chlorthalidone
Procedure for Example 3
Azilsartan Medoxomil granulation part
1. Azilsartan Medoxomil Monopotassium along with intragranular excipients mannitol, microcrystalline cellulose and hydroxypropyl cellulose were dispensed and sifted in quadro sifter.
2. Sifted material of step 1 was dry mixed in rapid mixer granulator for 10-15 minutes.
3. The dry mix material of step 2 was granulated with acetone.
4. The granulated wet mass was dried in rapid dryer at 50-60°C and dried material was milled in quadro co-mill.
Placebo granulation part Intragranular excipients mannitol and microcrystalline cellulose were dispensed and sifted in quadro sifter. Purified water was taken in container and added to 37% w/v hydrochloric acid. A pH of 1% w/w acidified water is 5.6-5.7. Sifted material of step 1 was dry mixed in rapid mixer granulator for 10-15 minutes. The dry mix material of step 3 was granulated with acidified water of step
2. The granulated wet mass was dried in rapid dryer at 50-60°C and dried material was milled in quadro co-mill.
Chlorthalidone granulation part Intragranular excipients mannitol, microcrystalline cellulose and crospovidone were dispensed and sifted in quadro sifter. Chlorthalidone was dissolved in methanol. Sifted material of step 1 was loaded in fluidized bed processor (FBP). Material of step 3 was wet granulated in FBP with the drug solution of step 2. The granulated wet mass was dried in rapid dryer at 50-60°C and dried material was milled in quadro co-mill.
Compression and coating Extragranular material containing crospovidone and magnesium stearate were dispensed and sifted through quadro sifter. The sifted material of step 1 was blended with Azilsartan granules, chlorthalidone granules and placebo granules in a bin blender for 10-15 minutes. The lubricated blend was compressed using suitable punch tooling. Opadry was dispersed in water under stirring.
5. The compressed tablets were film coated with aqueous dispersion of step 4 in a perforated coating pan.
Example 4
Table 4 - Pharmaceutical composition of Azilsartan and Chlorthalidone
Procedure for Example 4
Azilsartan kamedoxomil granulation part
1. Azilsartan Medoxomil Monopotassium along with intragranular excipients mannitol, microcrystalline cellulose and hydroxypropyl cellulose were dispensed and sifted in quadro sifter.
2. Hydrochloric acid (37% w/v) was taken in container and added to acetone. A pH of 1% w/w acidified acetone is 5.8-6.1.
3. Sifted material of step 1 was dry mixed in rapid mixer granulator for 10-15 minutes.
4. The dry mix material of step 4 was granulated with acidified acetone of step 3.
5. The granulated wet mass was dried in rapid dryer at 50-60°C and dried material was milled in quadro co-mill.
Chlorthalidone granulation part
1. Intragranular excipients mannitol, microcrystalline cellulose and crospovidone were dispensed and sifted in quadro sifter.
2. Chlorthalidone was dissolved in methanol.
3. Sifted material of step 1 was loaded in fluidized bed processor (FBP).
4. Material of step 3 was wet granulated in FBP with the drug solution of step 2.
5. The granulated wet mass was dried in rapid dryer at 50-60°C and dried material was milled in quadro co-mill.
Compression and coating
1. Extragranular material containing mannitol, microcrystalline cellulose, crospovidone and magnesium stearate were dispensed and sifted through quadro sifter.
2. The sifted material of step 1 was blended with Azilsartan and chlorthalidone granules in a bin blender for 10-15 minutes.
3. The lubricated blend was compressed using suitable punch tooling.
4. Opadry was dispersed in water under stirring.
5. The compressed tablets were film coated with aqueous dispersion of step 4 in a perforated coating pan.
Example 5 - Dissolution study
Dissolution study was performed on the formulations obtained in example 2, 3 and 4 in comparison to that of Edarbyclor (azilsartan medoxomil and
chlorthalidone) tablets 40mg/25mg in 900 mL pH 6.8 Phosphate Buffer with 1% Tween 80 at 50 RPM in USP Type 2 apparatus (Paddle). The results are presented in Table 5.
Table 5
* % drug release
Example 6 - Stability study
Organic impurities in azilsartan medoxomil and chlorthalidone tablets 40mg/25mg was determined by HPLC method and the results are presented in the Table 6, 7 & 8.
Table 6 - Stability study for Example 2:
Table 7- Stability study for Example 3:
Table 8- Stability study for Example 4:
Example 8 - Bioequivalence study:
An open label, balanced, randomized, single oral dose, crossover, oral bioequivalence study of Azilsartan medoxomil and Chlorthalidone Tablets 40/25 mg in comparison with EDARBYCLOR® (Azilsartan medoxomil and Chlorthalidone Tablets) 40/25 mg tablets (Marketed by Azurity Pharmaceuticals Inc) was performed in healthy, adult, human subjects under fasting and fed conditions.
The outcome of bioequivalence study for Azilsartan medoxomil and chlorthalidone compositions of the present invention under fed and fasting state complies with pre-defined bioequivalence criteria for Cmax,AUCO-t andAUCO-co.
Claims
1. A solid oral pharmaceutical composition comprising: Azilsartan or a pharmaceutically acceptable salt thereof; Chlorthalidone or a pharmaceutically acceptable salt thereof; a pH control agent, which provide a pH of more than 5 and one or more pharmaceutically acceptable excipients.
2. The solid oral pharmaceutical composition according to claim 1, wherein the composition contains pH control agent which provides a pH of more than 5, preferably about 5.0 to about 7.0, preferably about 5.0 to about 6.0 and more preferably about 5.5 to 6.0 when dissolved or suspended in water at a concentration of 1% w/v at 25° C.
3. The solid oral pharmaceutical composition according to claim 1, wherein the pH control agent is selected from group comprising strong acid such as hydrochloric acid, sulfuric acid, phosphoric acid ; basic substance such as inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogen carbonate, magnesium carbonate, calcium carbonate, magnesium oxide, ammonia, synthetic hydrotalcite ; organic bases such as basic amino acid such as lysine, arginine, meglumine ; methacrylic acid copolymer such as methacrylic acid and ethyl acrylate copolymer.
4. The solid oral pharmaceutical composition according to claim 1, wherein the pH control agent comprising hydrochloric acid.
5. The solid oral pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable excipient is selected from a group comprising diluents, binders, disintegrants, lubricants.
The solid oral pharmaceutical composition according to claim 1 wherein the solid pharmaceutical composition is a tablet. The solid oral pharmaceutical composition according to claim 1 can be prepared by wet granulation process such as using rapid mixer granulator or fluidized bed processor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202221029541 | 2022-05-23 | ||
| IN202221029541 | 2022-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023227997A1 true WO2023227997A1 (en) | 2023-11-30 |
Family
ID=88918620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2023/054928 WO2023227997A1 (en) | 2022-05-23 | 2023-05-12 | Pharmaceutical composition containing combination of azilsartan and chlorthalidone and process of preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023227997A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN202021028444A (en) * | 2020-07-03 | 2022-01-28 |
-
2023
- 2023-05-12 WO PCT/IB2023/054928 patent/WO2023227997A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN202021028444A (en) * | 2020-07-03 | 2022-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10874671B2 (en) | Pharmaceutical compositions of nilotinib | |
| WO2008064202A2 (en) | Modified-release formulations of calcium receptor-active compounds | |
| CA2801020A1 (en) | A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide | |
| CA2644179C (en) | Novel pharmaceutical composition comprising a disintegration matrix | |
| AU2007338359A1 (en) | Pharmaceutical formulation comprising neurokinin antagonist | |
| EP4076402A1 (en) | Dosage form comprising amorphous solid solution of empagliflozin with polymer | |
| US20090304755A1 (en) | Pharmaceutical formulation of losartan | |
| EP2701689B1 (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
| WO2005082329A2 (en) | Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide | |
| WO2014058047A1 (en) | Method for producing pharmaceutical preparation containing calcium antagonist/angiotensin ii receptor antagonist | |
| CA3089537A1 (en) | Pharmaceutical compositions comprising ibrutinib | |
| US11679105B1 (en) | Pharmaceutical compositions of cabozantinib | |
| WO2019180735A1 (en) | Stable pharmaceutical compositions comprising sacubitril-valsartan complex | |
| US20220387418A1 (en) | Pharmaceutical compositions of cabozantinib | |
| US20220362235A1 (en) | Pharmaceutical compositions of cabozantinib | |
| US20220280500A1 (en) | Pharmaceutical compositions of cabozantinib | |
| WO2023227997A1 (en) | Pharmaceutical composition containing combination of azilsartan and chlorthalidone and process of preparation thereof | |
| WO2020003196A1 (en) | Pharmaceutical composition of axitinib | |
| WO2018163199A1 (en) | "sustained release compositions of ranolazine" | |
| EP3761965A1 (en) | Ticagrelor-containing tablet formulation | |
| EP4279075A1 (en) | A pharmaceutical composition comprising elagolix | |
| WO2022029798A1 (en) | Pharmaceutical compositions comprising ribociclib | |
| WO2022153330A1 (en) | Pharmaceutical compositions comprising acalabrutinib | |
| US20240131018A1 (en) | Pharmaceutical compositions of cabozantinib | |
| WO2022162687A1 (en) | Pharmaceutical compositions comprising nilotinib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23811253 Country of ref document: EP Kind code of ref document: A1 |